Allergan PLC (AGN)

230.74
7.00 3.00
NYSE : Health Care
Prev Close 237.79
Open 237.05
Day Low/High 229.61 / 238.13
52 Wk Low/High 195.50 / 322.68
Volume 4.36M
Avg Volume 3.01M
Exchange NYSE
Shares Outstanding 395.95M
Market Cap 94.78B
EPS 10.00
P/E Ratio 19.35
Div & Yield N.A. (N.A)

Latest News

5 Stocks Hedge Funds Hate -- Should You Too?

5 Stocks Hedge Funds Hate -- Should You Too?

The stocks that professional investors hate the most might just be telling you something this fall…

Orange County Business Council Study Showcases Economic Impact Of Allergan On California Economy

Orange County Business Council Study Showcases Economic Impact Of Allergan On California Economy

-- California operations generate annual economic activity of more than $6 billion; net economic impact of $3.45 billion --

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

The company has spent $600 million weighing a potential breakup.

Weekly Roundup

With the Fed decision behind it, the market focuses on earnings and oil. In the portfolio, we added to three positions and exited from one.

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.

Investors Warm Up to Allergan Deals

CEO Saunders says initial impressions were misguided.

Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan

Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan

Cramer's a big fan of Flex' technology and says Walt Disney may look like a dog now but it will soon have its day.

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.

Allergan's Boldness may not be Limited to Tobira Deal

Allergan's Boldness may not be Limited to Tobira Deal

The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks add to gains on Wednesday afternoon after the Federal Reserve opts to leaves rates unchanged at its September meeting.

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks hold higher on Wednesday as investors await a policy decision from the Federal Reserve.

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock futures climb after the Bank of Japan makes moves to tackle deflation, while U.S. investors await a policy decision from their own central bank.

Jim Cramer's 'Mad Money' Recap: This Market Is Driving Me Mad!

Jim Cramer's 'Mad Money' Recap: This Market Is Driving Me Mad!

Gains from one day are being wiped out the next and vice versa, Cramer says.

How Will Allergan (AGN) Stock React to Akarna Therapeutics Deal?

How Will Allergan (AGN) Stock React to Akarna Therapeutics Deal?

Allergan (AGN) announced today that it would acquire Akarna Therapeutics for $50 million, marking its second acquisition of a company that specializes in fatty liver disease treatment.

Full Confidence in Allergan Deal

Tobira acquisition is in line with goals.

Allergan Acquires Akarna Therapeutics Adding To Its Strong Development Program And Commitment To Innovation In NASH

Allergan Acquires Akarna Therapeutics Adding To Its Strong Development Program And Commitment To Innovation In NASH

- Acquisition Adds Global Rights to AKN-083, a Potentially Best-in-Class Preclinical FXR Agonist for the Treatment of NASH -

Wall Street Creeps Higher Ahead of Fed Decision

Wall Street Creeps Higher Ahead of Fed Decision

Wall Street makes few big moves on Tuesday as investors opt to sit on the sidelines ahead of a major day of monetary policy news.

Cramer: What a Revoltin' Market Development This Is

Cramer: What a Revoltin' Market Development This Is

Stocks rally and then get smacked down in this inconsistent atmosphere.

Stocks Post Modest Gains as Fed Meets, Crude Higher

Stocks Post Modest Gains as Fed Meets, Crude Higher

Stocks move slightly higher Tuesday as nerves peak over how the Federal Reserve and the Bank of Japan will vote in their separate two-day meetings.

More Squawk From Jim Cramer: Allergan (AGN) Buying Tobira (TBRA) Looks Like 'Such an Overpay'

More Squawk From Jim Cramer: Allergan (AGN) Buying Tobira (TBRA) Looks Like 'Such an Overpay'

Allergen (AGN) said it would acquire Tobira Therapeutics (TBRA) for up to $1.7 billion on Tuesday.

Jim Cramer: Allergan Deal Looks Like an Overpay

Jim Cramer: Allergan Deal Looks Like an Overpay

Jim Cramer believes Allergan paid too much for Tobira unless CEO Brent Saunders can prove that he knows something about the company that other market participants do not.

Allergan's Chart Is Not Persuasive

Allergan's Chart Is Not Persuasive

Indicators driven by price and volume are not calling out for immediate purchase.

Stocks Rise as Wall Street Looks to Fed's Decision on Interest Rates

Stocks Rise as Wall Street Looks to Fed's Decision on Interest Rates

Stocks are higher Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.

Allergan (AGN) Stock Down After Tobira Therapeutics Deal

Allergan (AGN) Stock Down After Tobira Therapeutics Deal

Allergan (AGN) agreed to acquire Tobira Therapeutics (TBRA) for up to $1.695 billion on Tuesday.

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

What to do with $40 billion? That is the question facing Allergan (AGN). One biotechnology stock which stands out as a potential target for Allergan is Applied Genetic Technologies (AGTC).

Stock Futures Hold Higher as Housing Starts Slow

Stock Futures Hold Higher as Housing Starts Slow

Stock futures move higher on Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.